Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises

Novo NordiskThe International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk today announced a partnership to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world.

The partnership has three building blocks:

  • Ensuring efficient supply of low-cost human insulin in vials to Red Cross operations globally
  • Novo Nordisk support for ICRC's and DRC's health programmes, including efforts to improve NCD prevention and care
  • 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years

Today, more than 65 million people are fleeing conflict. Humanitarian and health actors have historically focused their efforts on the acute health threats people face, such as injuries and infectious diseases. Yet, the health needs of people in humanitarian settings, including those who are forcibly displaced and the communities that host them, are far greater.

"Non-communicable diseases are a silent killer and often overlooked during times of armed conflict. All people need access to appropriate health infrastructure and medicines to manage their health. If you look at Yemen, Syria, Iraq and beyond, thousands will remain with life-threatening illnesses if they are not able to receive essential medical supplies such as insulin to treat diabetes," says Peter Maurer, president of the ICRC.

For people living in humanitarian crises, the risk of exacerbating their chronic conditions such as diabetes and hypertension is 2-3 times higher than it was beforehand. It is estimated that diabetes is the cause of one in four limb amputations in patients at ICRC Physical Rehabilitation Centres in Yemen, Syria and Iraq.[1]

The partnership will aspire to break new ground for ultimately meeting the urgent needs of millions of vulnerable people living with NCDs.

"Our three organisations are committed to addressing these unmet health needs through an explorative partnership that combines our respective areas of expertise," says Lars Fruergaard Jørgensen, CEO of Novo Nordisk.

Anders Ladekarl, secretary general in the Danish Red Cross adds: "As partner organisations we will use our influence and scale to do more to address the needs of people living with NCDs in humanitarian crisis, and advocate together with other humanitarian and health actors to promote this agenda. This partnership is a first step in realising our collective aspiration that all people with NCDs in humanitarian settings have access to care."

To ensure solid data collection and evidence generation, the partnership will collaborate with the Health in Humanitarian Crises Centre at the London School of Hygiene and Tropical Medicine (LSHTM) with Director Karl Blanchet as the lead academic partner.

Each partner will contribute to the partnership in the following ways:

The ICRC will contribute its expertise of humanitarian operations and response, especially on providing healthcare to vulnerable populations in fragile and violent settings. Together with the DRC, the ICRC will lead the implementation of demonstration projects on the ground, including identifying people in need of treatment for diabetes and hypertension through the existing network of ICRC-supported health facilities.

The DRC will contribute its knowledge on community health outreach and capacity building activities in humanitarian settings with a focus on prevention and management of chronic diseases. It will facilitate access to nationwide networks of civil society groups, providing relevant services in their specific local contexts. It will mobilize staff and volunteers, including health professionals, with significant experience in humanitarian operations and response.

Novo Nordisk will adapt its ordering and production procedures to better serve the needs of humanitarian organisations as well as share its knowledge on handling and distributing cold chain products. It will share its wide experience of building capacity to widen access to diabetes care, including supporting the development of educational materials on diabetes prevention and care for a humanitarian context. The financial contribution to the partnership amounts to 21.5 million Danish kroner.

The role of LSHTM will be to conduct needs assessment, guide the design of interventions and evaluate the interventions to improve NCD prevention and care in humanitarian settings.

About the partner organisations

The ICRC helps people around the world affected by armed conflict and other situations of violence, doing everything possible to protect their dignity and relieve their suffering, often together with its Red Cross and Red Crescent partners. The ICRC also seeks to prevent hardship by promoting and strengthening humanitarian law and universal humanitarian principles.

Danish Red Cross (DRC) supports vulnerable people to live safe and healthy lives in humanitarian and development settings as well as in Denmark. The Danish Red Cross equips people with the tools they need to strengthen their resilience. DRC supports people on both sides of a conflict and in the remotest corners of the world with a special expertise in community-based health services.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries.

1. Perone SA, Martinez E, du Mortier S, et al. Non-communicable diseases in humanitarian settings: ten essential questions. Conflict and health. 2017;11(1):17. Halford G. Prevalence of Diabetes in ICRC Supported Physical Rehabilitation Centers for Disease Control Prevention. 2016.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...